Eight cyclosporine (GsA) metabolites were isolated from the urine of renal-transplant patients by high-pressure liquid chromatography. Structure and purity of the metabolites were assessed by fast atomic bombardment/mass spectroscopy, by proton nuclear magnetic resonance (NMR), and, when the quantity of metabolites permitted, by '3C-NMR. The immunosuppressive activities (I) of the metabolites were tested in three separate in vitro systems: primary and secondary mixed lymphocyte reactions as well as by a mitogenstimulated system. The I, as measured by comparing the concentration of each metabolite required for 50% inhibition of incorporation of [3H]thymidine, varied among the assay systems, as did the ranking of I among the test systems. In general, the I of most metabolites in all assay systems were <10% of that for GsA. Metabolites with single modifications exhibited the greatest I; e.g., that of M-17 was =16% of that of C5A (potency ratio 0.16) in a secondary mixed lymphocyte reaction. The significance of these findings in relation to therapeutic monitoring of CsA is discussed. (7, 8) . Yet the role of the metabolites in overall immunosuppression and toxicity remains uncertain.
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ing the uncertain purity of the metabolites.
In some instances, only high-pressure liquid chromatography
(HPLC)
has been used to assess purity (1, 3, 4, 9-16). Moreover, different in vitro assays have been used to assess immunosuppressive activity (1, 3,4, 9-16). However, CsA metabolites reportedly (10) have a relatively greater inhibitory effect on alloreactive T cells, including those found in cellular infiltrates of allografts, than on the primary activation of T cells.
We report here a comparison of the in vitro immunosuppressive properties of a large series of CsA metabolites isolated from the urine of renal-transplant recipients. The structure and purity of the metabolites were confirmed by fast atomic bombardment/mass spectroscopy (FABIMS) as well as 1H-NMR and, in some cases, depending on availability of metabolites, '3C-NMR. We also performed several in vitro assays with human peripheral-blood mononuclear cells (PBMC) to address the problem of methodological differences previously encountered in assessment of immunosuppressive activity.
Materials and Methods

Isolation of Cyclosporine Metabolites
We isolated CsA metabolites from the urine of renaltransplant recipients receiving CsA, by a procedure previously described (17) , modified as follows. To a 40-to 50-mL aliquot of urine (pH adjusted to 10.0 with 2 mol/L NaOH) add 50 to 60 mL of "HPLC-grade" diethyl ether, shake the mixture for 10 mm, and remove the urine layer. Using the same ether layer, extract two more such portions of the urine specimen. Then add 50 mL of 0.2 mol/L HC1 to the ether layer and shake the mixture for 10 mm. Remove and evaporate the ether layer and reconstitute the residue in 500 L of mobile phase (acetonitrile/methanollwater; 40/20/40 by vol). After adding 500 L of hexane to this, vortex-mix the sample for 30 s, then centrifuge (2000 x 5 mm). Discard the hexane (upper) layer and collect the remaining solvent layer for subsequent separation by HPLC.
For our isocratic chromatographic separation of CsA metabolites we used a Model 5000 chromatograph (Varian Inc., Walnut Creek, CA), with a 25 X 0.46 cm column of 5-.tm Spherasorb C-8 particles (Chromatography Sciences Inc., Rexdale, Ontario, Canada)-preceded by two precoluinns, one of pellicular silica and the other of RP-8 (Upchurch Scientific, Oak Harbor, WA)-and the mobile phase described above. In some instances, we used a tandem C-8 column and decreased the concentration of acetonitrile in the mobile phase to improve chromatographic resolution. The flow rate of the solvent was 1.0 mL/min; the column temperature was maintained at 70#{176}C. Eluent fractions corresponding to the peaks were collected manually, and the mobile phase was evaporated under low heat. Corresponding fractions from multiple injections were pooled for subsequent experiments. Identification xenon was used as the bombardment gas, and the resulting positive ions were extracted into the mass analyzer. A mass range of 100 to 1500 Da was scanned.
Nuclear magnetic resonance (NMR). We analyzed the proton and '3C-NMR spectra of the CsA metabolites at 300 MHz in CDC12, using a Model WH9O/AAM300 NMR (Bruker Instruments Inc., Silberstreiten, F.R.G.) and tetramethylsilane as the internal standard (3).
Immunological Studies
To study inhibition of lymphocyte proliferation by CsA and its metabolites, we used PBMC isolated from heparinized blood by Ficoll-Hypaque density-gradient centrifugation (18). The blood donors were ostensibly healthy hospital personnel.
The immunosuppressive activity of CsA and metabolites was examined in three ways, as previously described (19) We cultured 100 L of responder PBMC (1 x 106/mL) with 100 L of a pool (10 donors) of irradiated (25 Gy, or 2500 rads) stimulator PBMC in complete medium. The latter were irradiated to prevent their proliferation. Assays were run in quadruplicate in 96-well round-bottom microtiter trays for six days with or without (control) CsA or metabolite, with an 18-h terminal pulse of [3Hjlthymidine (0.3 pCi per well).
Secondary mixed-lymphocyte culture (2#{176} MLC). We cultured 10 x 106/mL responder PBMC with 10 x 106/mL irradiated (2500 rad) stimulator PBMC (pool of 10 donors) in a total volume of 10 mL of complete medium for six days. In preliminary experiments we found that the diluent alone at the highest concentration (equal to the most concentrated CsA sample) had no immunosuppressive effect on the proliferation of the PBMC; therefore, we used it as the control in each experiment. The concentrations of CsA and metabolites used to generate dose-response curves ranged from 2.0 to 20000 g/L (CsA and metabolite concentrations confirmed by HPLC). We determined the 50% inhibitory concentration (IC50) for CsA and each metabolite, then compared the potency ratio of each metabolite with that of CsA, i.e., IC50 of CsA/IC50 of metabolite. 
Results
Metabolite Purification
Peak C. The protonated molecular ion was at m/z 1205 (MW), which is a 2-Da increase over CsA. We considered this to be due to the addition of one oxygen (+ 16 Da) and loss of one methyl group (-14 Da). The presence of a fragment with an m/z of 1092 indicated that there was no modification on the side chain of amino acid 1. This was confirmed by 1H-NMR, in which no shift in the i1CH3 peak of amino acid 1 was observed. A loss of one of the seven N-CH3 singlets corresponding to amino acid 4 with the presence of five NH doublets indicated that demethylation had occurred at amino acid 4. We identified this compound as a hydroxylated demethylated metabolite of CsA, tentatively M-13, according to the scheme of Maurer et a!. (5) .
Peak D. The protonated molecular ion was at m/z 1219 (MW), corresponding to a 16-Da increase over CsA, attributed to the addition of one oxygen group. The 'H-NMR and '3C-NMR indicated that the modification occurred at amino acid 1. This metabolite was identified as M-17. The FAB/MS, 'H-NMR, and '3C-NMR spectra for this metabolite are shown in Figures 2 and 3 .
Peak E. The protonated molecular ion was at m/z 1221 (MW), which indicates an 18-Da increase over CsA, considered to be due to the addition of one oxygen (+ 16 Da) and the addition of two hydrogen molecules (+2 Da). The presence of a 1090-Da fragment indicates that an addi-
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Fig. 3. 13C-NMRspectra of CsA (top) and M-17 (bottom)
The arrow (bottom) indicates the modified CH3 group of amino acid 1. This peak is absent from C5A tional oxygen and hydrogen were contained in amino acid 1. The 'H-NMR confirmed the modification on amino acid 1. The latter procedure also indicated that there had been no demethylation. We identified this compound as a hydroxylated metabolite of CsA in which the double bond of amino acid 1 is saturated.
Peak F. The protonated molecular ion was at m/z 1219 (MW), which is a 16-Da increase over CsA. The presence of a 1106-Da fragment indicated that no modification had occurred on amino acid 1. The 'H-NMR confirmed this finding. We identified this compound as a monohydroxylated metabolite, tentatively M-1, according to the scheme of Maurer et al. (5) .
Peak G. The protonated molecular ion was at m/z 1219 (MW), a 16-Da increase over CsA, which we ascribed to the addition of one oxygen group. The presence of a 1090-Da fragment indicated that the oxygen was contained in amino acid 1. The shift of the CH3 peak in the 1H-NMR spectra conflnns a modification of amino acid 1. We tentatively identified this compound as M-18 according to the scheme of Maurer et al. (5) .
Peak H. The protonated molecular ion was at mfz 1189 (MW), a 14-Da decrease from CsA, which we ascribed to the loss of one methyl group (-14 Da). A fragment of 1076 Da was identified, indicating no modification to amino acid 1. The 1H-NMR indicated the loss of one of the N-CH3 singlets corresponding to amino acid 4, with an additional NH doublet being observed. We identified this compound as M-21 (5). The FAB/MS and 'H-NMR spectra of this metabolite are shown in Figure 4 .
Immunosuppressive Activity
We tested the immunosuppressive activity of the CsA ).
metabolitea on three separate occasions, using primary (1#{176}) and secondary (2#{176}) mixed-lymphocyte cultures as well as phytohemagglutinin-stimulated cultures. Table 1 shows the concentrations of the metabolites that result in 50% inhibition of [3H]thymidine uptake (IC50) in all three test systems.The potency ratios, defined as the ratio of IC60 of metabolites to that of CsA, are also shown. The IC50 of CsA as well as its metabolites varies from system to system. Significantly more CsA and metabolite was required to inhibit the phytohemagglutiin mitogen-stimulated systern as compared to the alloantigen-stimulated systems. The ranking of immunosuppressive activity of the metabolites relative to CsA also varies among the testing systems. All the metabolites tested have immunosuppressive activity <10% of CsA (potency ratio <0.10) except M-17 and M-1, which exhibit potency ratios of 0.16 and 0.14, respectively, in a 2#{176} MLC system. In contrast, M-1, M-17, and M-21 exhibit similar potencies in the 1#{176} MLC system, whereas M-1 is the most immunosuppressive in a phytohemagglutinin mitogen-stimulated system.
DiscussIon
This study was designed to assess the in vitro immunosuppressive effects of the various CsA metabolites that appear in urine from treated renal-transplant patients. A
-. prerequisite for the study was the procurement of CsA metabolites with known structure and purity. We isolated eight metabolites from the urine of renal-transplant recipients. We assessed the structure and purity of all metabolite fractions by FAB/MS and 'H-NMR, as well as 13C-NMR for one fraction (peak D). We were able to assign the structure of the compounds corresponding to peak C (M-13), peak D (M-17), and peak H (M-21). The structures of the other metabolites were tentatively identified according to the scheme of Maurer et al. (5) . Definitive structural identification of the remaining metabolites will be possible once sufficient quantities have been isolated to permit " analysis of all metabolites by '3C-NMR. All metabolite fractions were assessed to be free of contamination (>99% pure). The structural identity of the metabolites agrees with the recent report of Wang et al. (6) , who studied metabolites isolated from bile of transplant recipients, using FAB/MS and 1H-NMR. We also detected the presence of a novel monohydroxylated metabolite first reportedin this latter study in which the double bond in amino acid 1 was saturated (6) .
We tested the immunosuppressive activities of the metabolites simultaneously in three separate in vitro assay systems. We found the immunosuppressive activities of the metabolites to vary among the assay systems, with most of the metabolites having immunosuppressive activity <10% of that of CsA. This is consistent with the results of Ryffel et al. that this compound had an immunosuppressive activity about 80% that of CsA (15). These discrepancies may be due to differences in the purity of the metabolite fractions used as well as to differences among the assays used to assess immunosuppressive activity. In some instances, IC50 values or potency ratios for direct comparison of the metabolites and CsA are not reported (9, 10) . The present study, in which standardized techniques for metabolite isolation and identification as well as testing of immunosuppressive activity were used, may provide an insight into the matter. Nevertheless, what is consistent among the studies is that metabolites with single modifications-M-17, M-1 (hydroxylation), or M-21 (demethylation)-possess the most immunosuppressive activity, and that metabolites with two or more modifications possess substantially less. The overall contribution of CsA metabolites to imnumosuppressive activity in vitro still remains to be determined. M-17, which we and others have found to be the most immunosuppressive of all CsA metabolites (3, 4, 9-16), is present in concentrations exceeding those of CsA in the blood of kidney-, liver-, and heart-transplant patients (7,8). The concentrations of this and other metabolites in tissues have been shown to be severalfold higher than that of CsA itself (7, 8) . In liver-transplant patients where the metabolite/CsA ratios are higher, a better correlation with clinical responses was observed when both components were monitored in whole blood (20). The Task Force on CsA Monitoring recommends (21) that CsA should be monitored in whole blood with an assay specific for the parent compound, and that if any metabolites were shown to be active, specific assays for them should be instituted.
Although we and others have shown that CsA metabolites, in particular M-17, possess immunosuppressive activity, the requirement for its routine monitoring in cases such as renaltransplant patients, where the metabolite/parent CsA ratio is relatively constant (1), does not appear to be warranted. In other cases, such as in heart-and liver-transplant recipients, where higher and more variable metabolite concentrations are encountered (1), more clinical data are required before the need for routine clinical monitoring of metabolites can be ascertained.
